One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi

  • Cecilia Kanyama
  • , S. F. Molloy
  • , Adrienne K. Chan
  • , Duncan Lupiya
  • , Chimwemwe Chawinga
  • , Jack Adams
  • , Philip Bright
  • , David Lalloo
  • , Robert S. Heyderman
  • , Olivier Lortholary
  • , Shabbar Jaffar
  • , Angela Loyse
  • , Joep J. Van Oosterhout
  • , Mina C. Hosseinipour
  • , Thomas S. Harrison

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)

Abstract

In Malawi, 236 participants from the ACTA cryptococcal meningitis treatment trial were followed-up for 12 months. The trial outcomes reported at 10 weeks were sustained to 1 year. One-week amphotericinB plus flucytosine was associated with the lowest 1 year mortality (27.5% [95%CI: 16.3 to 44.1]).

Original languageEnglish
Pages (from-to)521-524
Number of pages4
JournalClinical Infectious Diseases
Volume70
Issue number3
Early online date1 Jun 2019
DOIs
Publication statusPublished - 1 Feb 2020

Keywords

  • Cryptococcal meningitis
  • HIV
  • Long-Term follow-up
  • Malawi
  • Treatment

Fingerprint

Dive into the research topics of 'One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi'. Together they form a unique fingerprint.

Cite this